NEW YORK (GenomeWeb) – The Parkinson's Institute and Clinical Center announced on Friday a collaboration with Germany's Centogene on panel-based genetic screening for a US patient cohort.
Under the partnership, patients will be screened using a large, customized panel to characterize genetic variants associated with development and treatment of Parkinson's disease.
Centogene will perform the genetic characterization at its CLIA-certified labs in Germany. The firm offers genetic diagnostic testing for rare hereditary diseases for patients worldwide, including next-generation sequencing-based whole-exome and whole-genome analysis.
"Centogene's expertise ingenetic characterization will help us to apply the right treatment for patients now and offer themhope for the future," PI CEO Carrolee Barlow said in a statement.
Financial and other terms of the alliance were not disclosed.